DANTROLENE
Standard Prescription
dantrolene__mg PO__(frequency) (__mg/kg/24hr)
dantrolene__mg (__mg/kg/dose) IV Q__H to maximum of __ (max __mg/kg)
Dosages
Spasticity
Children >5 years:
Initial: 0.5 mg/kg/dose (max 25 mg/dose) PO once daily or BID x 7 days
Malignant Hyperthermia
2.5 mg/kg IV, repeat q5-10min until patient is stabilized. A ceiling dose of 10 mg/kg is recommended, however, >10 mg/kg may be required for patients with persistent contractures or rigidity
Children >5 years:
Initial: 0.5 mg/kg/dose (max 25 mg/dose) PO once daily or BID x 7 days
Increment: Increase frequency to TID x 7 days then increase to 1 mg/kg/dose PO TID (max 50 mg/dose) x 7 days, then 2 mg/kg/dose PO TID (max 100 mg/dose).
Maximum: 12 mg/kg/24 hr or 400 mg/24 hr, whichever is lower.
Malignant Hyperthermia
2.5 mg/kg IV, repeat q5-10min until patient is stabilized. A ceiling dose of 10 mg/kg is recommended, however, >10 mg/kg may be required for patients with persistent contractures or rigidity
Mechanism of Action
Skeletal muscle relaxant
Forms Supplied
capsule: 25 mg, 100 mg
injection: 20 mg/vial
injection: 20 mg/vial
Comments
Titrate to desired effect.
Adverse effects include weakness, drowsiness, and irritability when used for spasticity.
Malignant Hyperthermia
Key indicators of stability include: declining or normal ETCO2, absence of dysrhythmias, resolving hyperthermia and rigidity
References
44, 128, 463, 495 - 497
Last Edited
2021-08-01 20:51:35